The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines
- 9 June 2010
- journal article
- Published by Springer Science and Business Media LLC in Investigational New Drugs
- Vol. 29 (6), 1224-1229
- https://doi.org/10.1007/s10637-010-9467-6
Abstract
Although platinum based therapy has improved short term survival of patients with metastatic ovarian cancer, the majority of patients continue to relapse and eventually die of their disease. Currently, a plethora of agents are in development, but how to combine them to enhance efficacy remains largely empiric. We have used short in vitro culture of defined cell lines with application of promising agents and analysis for cell death using a MTT assay to identify potentially useful combinations. Using median effect analysis, curve shift analysis and apoptosis assays, we can identify when agents are synergistic or antagonistic when applied together. Up to three agents can be studied in combination. Using three cell lines: SK-OV3, CaOV-3, and ES-2 (a clear cell tumor), we have identified that panobinostat (LBH-589), a broad histone deacetylase inhibitor in clinical trials, demonstrates global synergy with gemcitabine, with paclitaxel, and additive to synergistic effects with 5′DFUR. The triplet of panobinostat, doxorubicin, and carboplatin is especially synergistic in these cell lines. These effects are cytotoxic and not cytostatic. As all these agents are used clinically, we have identified combinations which warrant further investigation.Keywords
This publication has 37 references indexed in Scilit:
- Clinical Studies of Histone Deacetylase InhibitorsClinical Cancer Research, 2009
- The biology of ovarian cancer: new opportunities for translationNature Reviews Cancer, 2009
- Management of Recurrent Ovarian Carcinoma: Current Status and Future DirectionsSeminars in Oncology, 2009
- The Cytoplasmic Deacetylase HDAC6 Is Required for Efficient Oncogenic TumorigenesisCancer Research, 2008
- The aggresome pathway as a target for therapy in hematologic malignanciesMolecular Genetics and Metabolism, 2008
- Preclinicalversusclinical drug combination studiesLeukemia & Lymphoma, 2008
- Mutation analysis of 24 known cancer genes in the NCI-60 cell line setMolecular Cancer Therapeutics, 2006
- Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitroBreast Cancer Research and Treatment, 2006
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Evaluation of Combination ChemotherapyClinical Cancer Research, 2004